CA2995823A1 - Treatment and prevention of muscle loss using l-ornithine in combination with at least one of phenylacetate and phenylbutyrate - Google Patents

Treatment and prevention of muscle loss using l-ornithine in combination with at least one of phenylacetate and phenylbutyrate Download PDF

Info

Publication number
CA2995823A1
CA2995823A1 CA2995823A CA2995823A CA2995823A1 CA 2995823 A1 CA2995823 A1 CA 2995823A1 CA 2995823 A CA2995823 A CA 2995823A CA 2995823 A CA2995823 A CA 2995823A CA 2995823 A1 CA2995823 A1 CA 2995823A1
Authority
CA
Canada
Prior art keywords
muscle
loss
condition
phenylacetate
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA2995823A
Other languages
English (en)
French (fr)
Inventor
Christopher F. Rose
Franck Rousseau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ocera Therapeutics Inc
Original Assignee
Ocera Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ocera Therapeutics Inc filed Critical Ocera Therapeutics Inc
Publication of CA2995823A1 publication Critical patent/CA2995823A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/42—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving phosphatase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/08—Hepato-biliairy disorders other than hepatitis
    • G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2995823A 2015-08-18 2016-08-16 Treatment and prevention of muscle loss using l-ornithine in combination with at least one of phenylacetate and phenylbutyrate Pending CA2995823A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562206466P 2015-08-18 2015-08-18
US62/206,466 2015-08-18
PCT/US2016/047211 WO2017031131A1 (en) 2015-08-18 2016-08-16 Treatment and prevention of muscle loss using l-ornithine in combination with at least one of phenylacetate and phenylbutyrate

Publications (1)

Publication Number Publication Date
CA2995823A1 true CA2995823A1 (en) 2017-02-23

Family

ID=58051237

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2995823A Pending CA2995823A1 (en) 2015-08-18 2016-08-16 Treatment and prevention of muscle loss using l-ornithine in combination with at least one of phenylacetate and phenylbutyrate

Country Status (7)

Country Link
US (1) US10835506B2 (cg-RX-API-DMAC7.html)
EP (1) EP3337473A4 (cg-RX-API-DMAC7.html)
JP (1) JP6990170B2 (cg-RX-API-DMAC7.html)
AU (1) AU2016308641B2 (cg-RX-API-DMAC7.html)
CA (1) CA2995823A1 (cg-RX-API-DMAC7.html)
HK (1) HK1249434A1 (cg-RX-API-DMAC7.html)
WO (1) WO2017031131A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ708458A (en) 2009-04-03 2017-02-24 Ocera Therapeutics Inc L-ornithine phenyl acetate and methods of making thereof
EA025735B1 (ru) 2009-06-08 2017-01-30 ЮСиЭл БИЗНЕС ПиЭлСи Способ лечения портальной гипертензии с использованием l-орнитина в сочетании по меньшей мере с одним из соединений, выбранных из фенилацетата и фенилбутирата
NZ732632A (en) 2014-11-24 2021-07-30 Ucl Business Ltd Treatment of diseases associated with hepatic stellate cell activation using ammonia-lowering therapies
CA3004331A1 (en) * 2015-11-13 2017-05-18 Ocera Therapeutics, Inc. Formulations of l-ornithine phenylacetate
JOP20190146A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
KR20200024145A (ko) 2017-05-11 2020-03-06 오세라 테라퓨틱스, 아이엔씨. L-오르니틴 페닐아세테이트의 제조방법
CN111295187A (zh) 2017-08-14 2020-06-16 胺细拉健康公司 用于治疗肝脏疾病的氨基酸组合物
JP2019214546A (ja) * 2018-06-11 2019-12-19 学校法人福岡大学 終末糖化産物生成抑制剤及び医薬組成物
AR115585A1 (es) 2018-06-20 2021-02-03 Axcella Health Inc Composiciones y métodos para el tratamiento de la infiltración de grasa en músculo
JP2022533569A (ja) 2019-05-09 2022-07-25 オセラ セラピューティクス， インコーポレイテッド 肝性脳症を評価および処置する方法

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB965637A (en) 1962-04-23 1964-08-06 Tanabe Seiyaku Co L-ornithine l-aspartate
NL302572A (cg-RX-API-DMAC7.html) 1962-12-27
GB1067742A (en) 1963-09-16 1967-05-03 Kyowa Hakko Kogyo Kk Process for the preparation of l-ornithine l-aspartate
ZA716628B (en) 1970-10-15 1972-06-28 Richardson Merrell Spa Composition and method for treatment of hepatic disease and mental fatigue
FR2113774A1 (en) 1970-11-13 1972-06-30 Roques Ets Prepn of l-ornithine salts with org acids - using silver oxides
US4100161A (en) 1974-04-15 1978-07-11 The Johns Hopkins University Promotion of protein synthesis and suppression of urea formation in the body by keto analogs of essential amino acids
US3950529A (en) 1975-02-03 1976-04-13 Massachusetts General Hospital Amino acid formulations for patients with liver disease and method of using same
US4320146A (en) 1978-03-17 1982-03-16 The Johns Hopkins University Treatment of hepatic and renal disorders with ornithine and arginine salts of branched chain keto acids
US4228099A (en) 1978-03-17 1980-10-14 The Johns Hopkins University Ornithine and arginine salts of branched chain keto acids and uses in treatment of hepatic and renal disorders
US4352814A (en) 1979-04-18 1982-10-05 The Johns Hopkins University Treatment of hepatic and renal disorders with mixed salts of essential or semi-essential amino acids and nitrogen-free analogs
US4284647A (en) 1980-03-31 1981-08-18 The Johns Hopkins University Process for waste nitrogen removal
US4457942A (en) 1982-08-20 1984-07-03 Brusilow Saul W Process for waste nitrogen removal
US4857555A (en) * 1985-09-12 1989-08-15 Brigham & Women's Hospital Method of treating catabolic dysfunction
US4783443A (en) 1986-03-03 1988-11-08 The University Of Chicago Amino acyl cephalosporin derivatives
US5139981A (en) 1987-06-24 1992-08-18 Union Carbide Chemicals & Plastics Technology Corporation Process for preparing silver(I)-exchanged resins
DE4020980C1 (cg-RX-API-DMAC7.html) 1990-07-02 1991-09-26 Degussa Ag, 6000 Frankfurt, De
US5591613A (en) 1990-07-02 1997-01-07 Degussa Aktiengesellschaft Method for the preparation of D-arginine and L-ornithine
JP3127484B2 (ja) 1991-02-28 2001-01-22 味の素株式会社 肝炎治療薬
US5767086A (en) 1992-04-03 1998-06-16 Terrapin Technologies, Inc. Bone marrow stimulation by certain glutathione analogs
US5571783A (en) 1993-03-09 1996-11-05 Clintec Nutrition Company Composition and method for treating patients with hepatic disease
JP3273578B2 (ja) 1993-09-21 2002-04-08 第一化学薬品株式会社 オルニチンと酸性アミノ酸類又はケト酸類との塩の製造法
US5856481A (en) 1994-07-28 1999-01-05 Syntex (U.S.A.) Inc. 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl)methoxy-1,3-propanediol derivative
IL139728A (en) 1995-01-09 2003-06-24 Penwest Pharmaceuticals Compan Aqueous slurry composition containing microcrystalline cellulose for preparing a pharmaceutical excipient
AU2251897A (en) 1996-02-13 1997-09-02 Trustees Of The University Of Pennsylvania, The Method of treating liver disorders
ZA986614B (en) 1997-07-25 1999-01-27 Gilead Sciences Nucleotide analog composition
GB9815567D0 (en) 1998-07-18 1998-09-16 Glaxo Group Ltd Antiviral compound
US6258849B1 (en) 1998-07-23 2001-07-10 Stanislaw R. Burzynski Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate
EP1179347A4 (en) 1999-05-21 2002-06-26 Takeda Chemical Industries Ltd CONTROL SUBSTANCES FOR LIVER FUNCTION
US6768024B1 (en) 2000-08-04 2004-07-27 Lion Bioscience Ag Triamine derivative melanocortin receptor ligands and methods of using same
JP3211824B1 (ja) 2000-10-26 2001-09-25 味の素株式会社 分岐鎖アミノ酸含有医薬用顆粒製剤とその製造方法
DE60233558D1 (de) 2001-03-15 2009-10-15 Takashi Abe Aminosäurezusammensetzungen zur linderung einer fehlfunktion der leber
US6503530B1 (en) 2001-11-01 2003-01-07 Chunghee Kimberly Kang Method of preventing development of severe metabolic derangement in inborn errors of metabolism
US20030105104A1 (en) 2001-11-27 2003-06-05 Burzynski Stanislaw R. Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy
US20030195255A1 (en) 2002-04-12 2003-10-16 Summar Marshall L. Method for treating hepatic encephalopathies
US20040229948A1 (en) 2002-04-12 2004-11-18 Summar Marshall L. Method for preventing hepatic encephalopathic episodes
CN1383815A (zh) 2002-05-08 2002-12-11 刘万忠 防治肝病、肝性脑病的鸟氨酸和门冬氨酸的复方制剂及其制备方法
US20040152784A1 (en) 2002-07-23 2004-08-05 Special Products Limited Pharmaceutical composition and method for treatment of a urea cycle deficiency or sickle-cell anaemia
AU2003261825A1 (en) 2002-08-30 2004-03-19 Ajinomoto Co., Inc. Therapeutic agent for hepatic disease
US20050059150A1 (en) 2003-09-17 2005-03-17 Becton, Dickinson And Company Environments that maintain function of primary liver cells
MXPA03009902A (es) 2003-10-29 2005-05-03 Manuel Francisco Lara Och Jose Compuestos para reducir la hiperamonemia en pacientes con cirrosis u otras incapacidad para la eliminacion de amonio.
AU2005216251B2 (en) 2004-02-23 2011-03-10 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
KR20110124317A (ko) 2004-05-06 2011-11-16 오스테올로지스 에이에스 금속 유기 염의 제조를 위한 고 수율 및 고속 합성 방법
WO2006059237A1 (en) 2004-08-30 2006-06-08 Lunamed, Inc. 4-phenylbutyric acid controlled-release formulations for therapeutic use
PT2153870E (pt) 2004-11-26 2014-03-12 Ucl Business Plc Composições compreendendo ornitina e fenilacetato ou fenilbutirato para tratamento de encefalopatia hepática
GB0426141D0 (en) 2004-11-26 2004-12-29 Ucl Biomedica Plc Treatment
WO2007077995A1 (ja) 2006-01-05 2007-07-12 Kyowa Hakko Kogyo Co., Ltd. 筋肉増量剤
CA2727088A1 (en) * 2008-06-04 2009-12-10 Phenolics, Llc Enteric-coated formulations of polyethylene glycol and one or more soluble amino acids for oral ingestion and enhanced uptake of same
NZ708458A (en) 2009-04-03 2017-02-24 Ocera Therapeutics Inc L-ornithine phenyl acetate and methods of making thereof
AU2015221466B2 (en) 2009-04-03 2017-02-02 Ocera Therapeutics, Inc. L-ornithine phenyl acetate and methods of making thereof
CA2763894A1 (en) 2009-06-02 2011-01-13 Salix Pharmaceuticals, Ltd. Use of rifaximin to maintain remission of hepatic encephalopathy
EA025735B1 (ru) * 2009-06-08 2017-01-30 ЮСиЭл БИЗНЕС ПиЭлСи Способ лечения портальной гипертензии с использованием l-орнитина в сочетании по меньшей мере с одним из соединений, выбранных из фенилацетата и фенилбутирата
AU2014250643B2 (en) 2009-06-08 2016-07-14 Ocera Therapeutics, Inc. Treatment of portal hypertension and restoration of liver function using L-ornithine phenylacetate
ES2720148T3 (es) 2010-10-06 2019-07-18 Ocera Therapeutics Inc Métodos de fabricación de fenilacetato de L-ornitina
ES2654774T3 (es) 2012-11-21 2018-02-15 Horizon Therapeutics, Llc Métodos para administrar y evaluar fármacos de recuperación de nitrógeno para el tratamiento de encefalopatía hepática
NZ732632A (en) 2014-11-24 2021-07-30 Ucl Business Ltd Treatment of diseases associated with hepatic stellate cell activation using ammonia-lowering therapies
EP3285756B1 (en) 2015-04-20 2023-02-22 Ocera Therapeutics, Inc. Formulations of l-ornithine phenylacetate
US11219611B2 (en) 2015-11-13 2022-01-11 Ocera Therapeutics, Inc. Formulations of L-ornithine phenylacetate

Also Published As

Publication number Publication date
JP2018523683A (ja) 2018-08-23
AU2016308641A1 (en) 2018-03-01
US20180221320A1 (en) 2018-08-09
HK1249434A1 (zh) 2018-11-02
AU2016308641B2 (en) 2022-02-03
JP6990170B2 (ja) 2022-01-12
WO2017031131A1 (en) 2017-02-23
EP3337473A1 (en) 2018-06-27
US10835506B2 (en) 2020-11-17
EP3337473A4 (en) 2019-04-17

Similar Documents

Publication Publication Date Title
US10835506B2 (en) Treatment and prevention of muscle loss using L-ornithine in combination with at least one of phenylacetate and phenylbutyrate
TWI492745B (zh) 合成的三萜系化合物及其使用於治療疾病之方法
Gaunitz et al. Carnosine and cancer: a perspective
JP6250588B2 (ja) Ｌ−オルニチンフェニル酢酸塩を用いる門脈圧亢進の治療及び肝機能の修復
US20120156139A1 (en) Isotopically labeled neurochemical agents and uses therof for diagnosing conditions and disorders
AU2016325556B2 (en) Treatment and prevention of neuronal cell loss using L-ornithine in combination with at least one of phenylacetate and phenylbutyrate
JP2013537545A (ja) 筋萎縮性側索硬化症（ａｌｓ）の治療に用いるためのジアゾキシド
AU2018280118A1 (en) Compositions for the treatment of fibrosis
CN107848970B (zh) 岩藻糖苷酶抑制剂
BR112019010249A2 (pt) método de tratamento de doença de armazenamento de glicogênio
US20200163908A1 (en) Methods and compositions for regulating glucose homeostasis
KR20150130352A (ko) 지방간 질환을 치료하는 방법
US20150297540A1 (en) Uses and Methods for the Treatment of Liver Diseases or Conditions
US20230142366A1 (en) Novel polymorphic forms of metopimazine
US20240335447A1 (en) Wee1 inhibitor for cancer
Dupuis et al. The ETA-receptor antagonist LU 135252 prevents the progression of established pulmonary hypertension induced by monocrotaline in rats
US20230105984A1 (en) Compositions and methods for the treatment of liver diseases and disorders
TWI906348B (zh) 脂肪性肝疾病之治療劑
JP7756126B2 (ja) 脂肪性肝疾患の治療薬
Leung et al. Augmented pulmonary vascular and venous constrictions to NG-nitro-L-arginine methyl ester in rats with monocrotaline-induced pulmonary hypertension
US10772882B2 (en) Pulmonary hypertension preventative or therapeutic agent containing crude drug
Kristensen et al. Negative inotropic and hypotensive effects of the superoxide dismutase mimetic tempol in pigs
WO2024006297A1 (en) Scd1 inhibitors for treating liver disease
EP4543542A2 (en) Treatment of non-alcoholic steatohepatitis and non-alcoholic fatty liver disease
EP4247358A1 (en) Antiviral therapeutic compounds and compositions for use in treatment of coronavirus and influenza virus

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210722

EEER Examination request

Effective date: 20210722

EEER Examination request

Effective date: 20210722

EEER Examination request

Effective date: 20210722

EEER Examination request

Effective date: 20210722

EEER Examination request

Effective date: 20210722

EEER Examination request

Effective date: 20210722

EEER Examination request

Effective date: 20210722